Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia

BACKGROUND: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. OBJECTIVES: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesti, Tanja, Sever, Maša, Ocvirk, Janja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Skin Cancer − Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808722/
https://www.ncbi.nlm.nih.gov/pubmed/35896082
http://dx.doi.org/10.1159/000525612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808722/
https://www.ncbi.nlm.nih.gov/pubmed/35896082
http://dx.doi.org/10.1159/000525612

Ejemplares similares